Nucl Med Mol Imaging.
2014 Mar;48(1):16-25.
Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer
- Affiliations
-
- 1Department of Nuclear Medicine, Chonnam National University Hospital, Gwangju 501-757, Republic of Korea. songhc@jnu.ac.kr
- 2Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Gwangju, Republic of Korea.
- 3Department of Internal Medicine, Chonnam National University Hwasun Hospital, Gwangju, Republic of Korea.
- 4Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Gwangju, Republic of Korea.
- 5Department of Nuclear Medicine, Chonnam National University Medical School and Hospital, 42, Jebong-no, Donggu, Gwangju 501-757, Republic of Korea.
Abstract
- PURPOSE
We evaluated the value of variable 18F-FDG PET/CT parameters for the prediction of disease progression after concurrent chemoradiotherapy (CCRT) in patients with inoperable stage III non-small-cell lung cancer (NSCLC).
METHODS
One hundred sixteen pretreatment FDG PET/CT scans of inoperable stage III NSCLC were retrospectively reviewed (stage IIIA: 51; stage IIIB: 65). The volume of interest was automatically drawn for each primary lung tumor, and PET parameters were assessed as follows: maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) using the boundaries presenting SUV intensity exceeding 3.0, and the area under the curve of the cumulative SUV-volume histograms (AUC-CSH), which is known to reflect the tumor heterogeneity. Progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were compared with each PET and clinical parameters by univariate and multivariate survival analysis.
RESULTS
In the ROC analysis, the optimal cutoff values of SUVmax, MTV (cm3), and AUC-CSH for prediction of PFS were determined as 21.5, 27.7, and 4,800, respectively. In univariate analysis, PFS was statistically significantly reduced in those with AUC-CSH<4,800 (p =0.004). In multivariate analysis, AUC-CSH and SUVmax were statistically significant independent prognostic factors (HR 3.35, 95 % CI 1.79-6.28, p <0.001; HR 0.25, 95%CI 0.09-0.70, p =0.008, respectively). Multivariate analysis showed that AUC-CSH was the most significant independent prognostic factor for LRFS and DMFS (HR 3.27, 95 % CI 1.54-6.94, p =0.002; HR 2.79, 95 % CI 1.42-5.50, p =0.003).
CONCLUSIONS
Intratumoral metabolic heterogeneity of primary lung tumor in 18F-FDG PET/CT can predict disease progression after CCRT in inoperable stage III NSCLC.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Definitive Radiotherapy of Non-Small Cell Lung Cancer
- Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
- Lack of the Difference in Outcome between N2 and N3 Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy; A Retrospective Analysis of 186 Patients
- Chemotherapy for Small Cell Lung Cancer
- Early Result of Surgical Resection after Pre-Operative Concurrent chemoradiotherapy for N2-Positive Stage IIIA NSCLC
